- Home
- WNW vs MBIO Comparison
WNW vs MBIO Comparison
Compare WNW & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- MBIO
- Stock Information
- Founded
- WNW 2015
- MBIO 2015
- Country
- WNW China
- MBIO United States
- Employees
- WNW N/A
- MBIO N/A
- Industry
- WNW Catalog/Specialty Distribution
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- MBIO Health Care
- Exchange
- WNW Nasdaq
- MBIO Nasdaq
- Market Cap
- WNW 5.4M
- MBIO 4.7M
- IPO Year
- WNW 2020
- MBIO N/A
- Fundamental
- Price
- WNW $1.86
- MBIO $1.43
- Analyst Decision
- WNW
- MBIO
- Analyst Count
- WNW 0
- MBIO 0
- Target Price
- WNW N/A
- MBIO N/A
- AVG Volume (30 Days)
- WNW 11.9K
- MBIO 147.7K
- Earning Date
- WNW 05-14-2025
- MBIO 11-07-2025
- Dividend Yield
- WNW N/A
- MBIO N/A
- EPS Growth
- WNW N/A
- MBIO N/A
- EPS
- WNW 9.06
- MBIO N/A
- Revenue
- WNW $158,485.00
- MBIO N/A
- Revenue This Year
- WNW N/A
- MBIO N/A
- Revenue Next Year
- WNW N/A
- MBIO N/A
- P/E Ratio
- WNW $0.21
- MBIO N/A
- Revenue Growth
- WNW N/A
- MBIO N/A
- 52 Week Low
- WNW $0.95
- MBIO $0.89
- 52 Week High
- WNW $70.00
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- WNW 58.73
- MBIO 39.31
- Support Level
- WNW $1.67
- MBIO $1.51
- Resistance Level
- WNW $1.76
- MBIO $1.59
- Average True Range (ATR)
- WNW 0.10
- MBIO 0.09
- MACD
- WNW 0.01
- MBIO -0.01
- Stochastic Oscillator
- WNW 86.44
- MBIO 2.89
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.